Please login to the form below

Not currently logged in
Email:
Password:

Genentech’s Sunil Agarwal joins rare disease firm

He will serve as chief medical officer at Ultragenyx

Dr Sunil Agarwal has left his senior role at Genentech to join rare disease specialist Ultragenyx Pharmaceutical as its chief medical officer.

Dr Agarwal was most recently global head of clinical development for immunology and infectious diseases, metabolism, neuroscience and ophthalmology at Genentech, which has been the biotech arm of Roche since its acquisition in 2009.

He spent just over 10 years at Genentech where his positions included senior VP for immunology and infectious diseases and VP for rheumatology.

In his new role at Ultragenyx Dr Agarwal will lead the California-based company's clinical operations, regulatory affairs and pharmacovigilance efforts as it advances its pipeline of orphan products for rare and ultra-rare diseases. These include KRN23, a drug in development for people who have low levels of phosphate in the blood.

Commenting on his appointment Dr Agarwal said: “To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of.”

25th July 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...